Mumbai : The Indian Pharmaceutical Market (IPM) has registered a growth of 6.6 per cent for the month of November 2021, after registering a growth of 5 per cent for the month of October 2021.

According to AIOCD AWACS report, moving annual total (MAT) has seen a growth of 15.2 per cent over the corresponding period of last year.

Among the top therapies, gastro, respiratory, pain analgesics and gynaec segment continue to show a robust growth for the month of November 21.

India Ratings and Research opines the 6.6% year on year revenue growth in India’s pharmaceutical market (IPM) during November 2021, was led by improving growth trends in chronic therapies, namely cardiac 6% year on year (October 2021: down 1% yoy) and anti-diabetic 6% year on year (October 2021: up 1% year on year ).

Acute therapies namely gastro-intestinal, respiratory and pain/analgesics continued to witnessed strong growth, aided by the low base impact.

During November 2021, volumes were flat year on year (October 2021: declined 1.6% year on year), while price growth was 5.4% (5.3%) and new products launches were 1.2% (1.4%), driven by acute therapy products.

Acute therapies such as gastro, respiratory and pain/analgesics witnessed sales growth of 13.1% year on year, 16.3% year on year and 17.3% year on year respectively. Growth improvement was observed in chronic therapies during the month, with cardiac growing 6.3% year on year and anti-diabetic reporting 6.0% year on year growth, the agency said.

During MAT Nov 2021, Macleods, Aristo and Emcure significantly outperformed the market, with year on year growth of 23.8%, 28.3% and 25.6%, respectively. This was led by higher sales of Covid-19 related products and the improving performance of acute therapies.

“The pandemic has pushed up sales of medicines and resulted in exponential growth for the pharmaceutical sector. The Indian pharma market (IPM) grew 6.1% year on year during November led by continued traction in the chronic segment. The acute segment also grew on a low base of last year. Covid therapy drugs that contributed to the pharma market growth during the first half of the year continued to add to the rise. Non-Covid drugs sales grew 6.7% year-on-year during November, surpassing the 6.3% sales growth of Covid drugs. Growth in volume terms, however, remained flat year-on-year during November. It was the 5.4% rise in prices and new product launches, driven by acute therapy products, that helped the IPM grow in the month,” said Nikkhil K Masurkar, executive director of Entod Pharmaceuticals.